SCHEMBL1145786

SCHEMBL1145786

CSC1CCCCCCC1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.32
SLC2A1 P11166 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6057174 1.00 ACHE (0.32) ACHESLC2A1ALDH1A1HSD17B10
SCHEMBL22388371 1.00 ACHE (0.32) ACHESLC2A1ALDH1A1HSD17B10
SCHEMBL22388432 1.00 ACHE (0.32) ACHESLC2A1ALDH1A1HSD17B10
SCHEMBL4194212 1.00
SCHEMBL1145601 1.00
SCHEMBL199625 1.00
Iodide SCHEMBL28948417 0.97 ACHE (0.31) ACHE
SCHEMBL722771 0.96
SCHEMBL721065 0.89
SCHEMBL12326322 0.82 ALDH1A1 (0.44) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4735711-A ORGANIC MONOSULFIDE THE DOW CHEMICAL COMPANY (US) 1988-04-05 US claimed
CN-115668571-A Electrolyte solution, electrochemical device, lithium ion secondary battery, module, and compound 大金工业株式会社 2023-01-31 CN disclosed
EP-3686199-B9 FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) 2022-12-07 EP disclosed
US-10844164-B2 Oligomer, composition and composite material employing the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-11-24 US disclosed
US-20180171068-A1 OLIGOMER, COMPOSITION AND COMPOSITE MATERIAL EMPLOYING THE SAME INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2018-06-21 US disclosed
US-9650456-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2017-05-16 US disclosed
EP-2825574-B1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORP (JP) 2016-02-24 EP disclosed
US-20150031845-A1 Process For Producing Polydienes BRIDGESTONE CORPORATION (JP) 2015-01-29 US disclosed
EP-2825574-A1 PROCESS FOR PRODUCING POLYDIENES Bridgestone Corporation (JP) 2015-01-21 EP disclosed
WO-2013138270-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTSONE CORPORATION (JP) 2013-09-19 WO disclosed
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists XIN ZHILI (US) 2005-08-04 US disclosed
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists KOSOGOF CHRISTI (US) 2005-08-04 US disclosed
WO-2005030734-A1 DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS ABBOTT LABORATORIES (US) 2005-04-07 WO disclosed
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators ABBOTT LABORATORIES 2005-03-31 US disclosed
US-4735711-A ORGANIC MONOSULFIDE THE DOW CHEMICAL COMPANY (US) 1988-04-05 US disclosed
US-4702822-A ORGANIC SULFIDE WITH ALKYL THIOCARBONATE, THIONACARBAMATEA, OR THIOPHOSPHATE THE DOW CHEMICAL COMPANY (US) 1987-10-27 US disclosed
US-4676890-A MIXTURE OF THIOALKYL AMINE AND HYDROCARBYL SULFIDES; SULFIDE ORES; PREFERENTIAL THE DOW CHEMICAL COMPANY (US) 1987-06-30 US disclosed
WO-1987003222-A1 COLLECTOR COMPOSITIONS FOR THE FROTH FLOTATION OF MINERAL VALUES THE DOW CHEMICAL COMPANY (US) 1987-06-04 WO disclosed
WO-1987000451-A1 NOVEL COLLECTOR COMPOSITION FOR FROTH FLOTATION THE DOW CHEMICAL COMPANY (US) 1987-01-29 WO disclosed
WO-1986006983-A1 NOVEL COLLECTORS FOR THE SELECTIVE FROTH FLOTATION OF SULFIDE MINERALS THE DOW CHEMICAL COMPANY (US) 1986-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 ACHE 4597/4885SLC2A1 151/4885ALDH1A1 2435/4885
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 ACHE 4665/4885SLC2A1 128/4885ALDH1A1 3084/4885
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators GPR119, GIPR, GCGR ACHE 4530/4885SLC2A1 297/4885ALDH1A1 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.